Navigation Links
Solving the 50-year-old puzzle of thalidomide
Date:11/17/2009

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer.

Thalidomide was used in over 46 countries following its launch in 1957, but its side effects led to over 10000 children being born with birth defects and the drug was subsequently banned in 1962. However, the drug is now experiencing a renaissance worldwide, particularly across Africa and South America where new cases of thalidomide-induced limb defects are now occurring. This, argues Dr Neil Vargesson of the University of Aberdeen, raises the urgency for research which can target and isolate the drug's negative side effects.

"The mere mention of thalidomide instils fear in some people to this day as it caused the biggest medical disaster in history," said Vargesson. "However it still raises hopes for the treatments of diseases such as Leprosy and multiple myeloma."

Dr Vargesson and his team were the first to demonstrate how the drug causes limb defects by targeting immature blood vessels and now this latest article attempts to link all previous models of thalidomide action together to create one central model. This model proposes that all thalidomide associated defects could be caused by the same 'common mechanism', primarily an effect on angiogenesis, the growth of new blood vessels.

The understanding that the drug's targeting of blood vessels is a 'common mechanism' and the root cause of thalidomide's other side effects raises the possibility of producing a safer form of the drug which can isolate this mechanism and retain clinical benefits.

"Understanding this mechanism resolves a 50-year-old puzzle," concluded Vargesson, "it answers the questions asked by scientists since the first cases were identified in 1958. The possibility of producing analogues of the drug for targeting specific conditions without the devastating side effects is now a very real possibility."


'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Celiac Disease Provides Clues To Solving Autoimmunity
2. Study finds autistics better at problem-solving
3. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
4. Body movements can influence problem solving, researchers report
5. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
6. Study shows potential for resolving type 2 diabetes with bariatric surgery
7. Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness
8. Resolving to Break an Addictive Habit?
9. New Strategies for the New Year: Resolving to break an addiction? Help from Harvard Medical School
10. Prevention is the Key to Solving Health Care Crisis;
11. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... , ... Ogawa World USA introduced the first of its kind Ogawa ... Application. The Smart 3D combines the best in technological advancement, design, and massage capability ... specialized massage program, each user has a tailored experience unparalleled by any other massage ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Canada’s top Information and Communication Technology (ICT) companies in the annual Branham300 listing. ... companies operating in Canada, as ranked by revenue. , “We are honored ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic ... of surgical procedure that can be used to diagnose and treat joint problems. During ... inserted. These instruments include a special lighting system and lens that illuminate and magnify ...
(Date:5/3/2016)... Fremont, California (PRWEB) , ... ... ... the leading provider of Microsoft secure remote access connectivity solutions, today announced ... deployed platform for Microsoft DirectAccess. The new Celestix SecureAccess release will enable ...
(Date:5/3/2016)... ... 2016 , ... LunchSkins is changing the future of ocean plastic ... throw away plastic baggies. The mission-driven bags give back to global leaders in the ... mission is all about reducing global plastic waste and we’ve teamed up ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016  In the next ten years, ... from systems dependent on CRTs monitors to those reliant ... CRT Medical monitors and will automatically sync to ... of foreseeable benefits to this technological advancement, it ... have to be replaced in order to be ...
(Date:4/29/2016)... 2016 Acquisition Expands the ... Development Capabilities in North America ... Indegene ( http://www.indegene.com ), a ... of Skura Corporation,s life science business. Skura,s SFX ... enablement technology for life science organizations and delivers ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
Breaking Medicine Technology: